Shares of Thermo Fisher Scientific (TMO) rose Thursday after the medical device maker's fourth-quarter results topped analysts' estimates.
Thermo Fisher reported revenue of $11.4 billion, up about 5% year-over-year and better than the $11.28 billion Visible Alpha consensus. Profit narrowly beat estimates at $1.83 billion, or $4.78 per share, up from $4.20 a year ago. Adjusted earnings per share (EPS) of $6.10 also topped expectations.
Sales increased across all four of the company's divisions, with revenue at its largest segment, Laboratory Products and Biopharma Services, rising 4%. Last quarter, shares fell as sales were flat or declined in two segments.
Thermo Fisher shares were up 6.6% intraday after entering Thursday roughly flat over the prior 12 months.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。